Skip to main content
Premium Trial:

Request an Annual Quote

Paracel Closes Down Operations

NEW YORK, Sept. 29 (GenomeWeb News) - Paracel, a Celera Genomics subsidiary, has closed down its operations, the company said yesterday.

 

In a notice posted on its website, the Pasadena, Calif.-based bioinformatics tool provider said that as of Sept. 28, it has discontinued all operations except for ongoing support to its current contract customers.

 

No further information was immediately available from Paracel.

 

Two years ago, GenomeWeb News reported that Paracel's future as a Celera unit was uncertain. The company has been providing genome researchers with bioinformatics hardware systems, including GeneMatcher and BlastMachine.

 

Paracel was founded in 1992 to commercialize data-filtering technology developed by TRW for government applications. Together with researchers from Caltech and Applied Biosystems, the firm programmed the FDF system for genomic data analysis.

The company became a wholly owned subsidiary of Applera after Celera acquired it in a stock-for-stock transaction in June 2000. The company is based in Pasadena, Calif., and has offices in San Jose, Calif., Columbia, Md., and the UK.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.